Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma

Haematologica. 2024 Apr 1;109(4):1269-1273. doi: 10.3324/haematol.2023.283802.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bispecific*
  • China
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Lymphoma, Non-Hodgkin*

Substances

  • glofitamab
  • Antibodies, Bispecific

Grants and funding

Funding: This study was funded by F. Hoffmann-La Roche Ltd.